Brachytherapy for Breast Cancer Follow Up

Back in 2007, when I was diagnosed and treated for my breast cancer, I heard about this new technique for the radiation portion of treatment,brachytherapy. I was jealous. It was not offered at my hospital. The big thing I liked was that it took so much less time for treatment.Breast cancer treatment takes a LONG time. I was diagnosed at the end of May, after two surgeries that went into July, I finished chemo in December, and needed one more surgery (don't ask). I was then facing 7 weeks of radiation. I just wanted to be done. Since brachytherapy wasn't available I had the standard radiation treatment. I couldn't even have the shorter radiation protocol where you go twice a day for a week (blanking on the name).Now, I was reading another article discussing breast biopsies in follow up breast cancer treatment. Buried in the article is this statement:" They looked at 41,510 breast cancer patients in MarketScan (the national database of patients with private insurance, age 64 years and younger), and 80,369 breast cancer patients in SEER-Medicare (patients age 65 years and older). All had Stage I - III disease and were diagnosed between 2000 and 2011. Diagnosis and procedural codes were used to identify biopsy rates during follow up.Five- and 10-year overall incidence of breast biopsy was 14.7 percent and 23.4 percent, respectively, in the MarketScan cohort, and 11.8 percent and 14.9 percent, respectively, in the SEER-Medicare cohort. Adjuvant chemotherapy use, patient age, ...
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: breast cancer treatment cancer research radiation Source Type: blogs

Related Links:

Condition:   Breast Cancer Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole Sponsors:   The Christie NHS Foundation Trust;   University of Manchester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Neutropenia;   Breast Cancer Interventions:   Drug: Eflapegrastim;   Drug: Docetaxel;   Drug: Cyclophosphamide Sponsor:   Spectrum Pharmaceuticals, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study included 516 women who underwent CESM imaging for screening and diagnostic purposes between 2012 and 2015 in a single center. BPE at CESM images was retrospectively, independently and blindly graded by six experienced radiologists using the following scale: minimal, mild, moderate, or marked. Agreement between readers was estimated using Kendall's W coefficient of concordance. Associations between clinical factors and BPE, and between BPE and breast cancer were examined using generalized estimating equations. Association between BPE and breast cancer was assessed for the whole study group, and for the screening ...
Source: Academic Radiology - Category: Radiology Source Type: research
Authors: Huang Q, Xu TY, Wu ZY Abstract BACKGROUND As the most aggressive breast cancer, inflammatory breast cancer (IBC) has a poor prognosis. However, analyzing the prognostic factors of IBC is challenging due to its rarity. We identified the prognostic factors to establish predictive tools for survival in nonmetastatic IBC patients who received tri-modality therapy. MATERIAL AND METHODS The data of 893 nonmetastatic IBC patients were acquired from the Surveillance, Epidemiology, and End Results (SEER) database. IBC was identified by "ICD-O-3=8530" or "AJCC T, 7th=T4d"). Patients were randomiz...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
ConclusionsIn this cohort of young women, population-based cancer registry data on chemotherapy receipt was reasonably accurate and complete in comparison with insurance claims. Radiation and hormone therapy appeared to be less complete.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
In conclusion, the present study may improve the understanding of the mechanisms of breast cancer and provide several valuable prognosis and treatment signatures. PMID: 31788055 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Guo F, Long L, Wang J, Wang Y, Liu Y, Wang L, Luo F Abstract Breast cancer is the most common malignant neoplasm in women worldwide, and the treatment regimens currently available are far from optimal. Targeted therapy, based on molecular typing of breast cancer, is the most precise form of treatment, and CXC chemokine receptor 2 (CXCR2) is one of the molecular markers used in targeted therapies. As a member of the seven transmembrane G-protein-coupled receptor family, CXCR2 and its associated ligands have been increasingly implicated in tumor-associated processes. These processes include proliferation, an...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, bioinformatics analysis revealed that ARHGAP9, 15, 19 and 30, but not other ARHGAP family genes may be promising targets with prognostic value and biological function for precision treatment of breast cancer. PMID: 31788076 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Guan X, Gu S, Yuan M, Zheng X, Wu J Abstract Drug resistance is a significant obstacle when treating triple-negative breast cancer (TNBC). Several studies have demonstrated that microRNAs (miRNAs) have essential roles in regulating drug resistance in different types of cancer. miR-33a-5p has previously been reported to be a tumor suppressor in several types of cancer. However, its role in breast cancer remains unknown. The present study aimed to investigate the role of miR-33a-5p in the chemoresistance of TNBC and uncover its potential molecular mechanisms. Cell Counting Kit-8 assay was used to examine cel...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Deocesano-Pereira C, Machado RAC, De Jesus-Ferreira HC, Marchini T, Pereira TF, Carreira ACO, Sogayar MC Abstract Long non-coding RNAs (lncRNAs) serve critical roles in regulating cellular homeostasis, and their deregulated expression/activity is associated with neoplastic transformation. The maternally expressed gene 3 (MEG3) has been extensively described as a tumor suppressor gene in different types of cancer, including breast cancer. Interestingly, using a panel of seven different breast cancer cell lines, the present study revealed that MEG3 is highly expressed in the triple negative metastatic human ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Blogging | Brachytherapy | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Endocrine Therapy | Hospitals | Insurance | Medicare | Study | Women